Assessment Of Change In Quality Of Life (QOL), Carcinoid Syndrome (CS) Symptoms, And Health Care Resource Utilization (HRU) In Cs Patients Treated With Somatostatin Analogs (SSA) -- Results From Longitudinal Patient Surveys